A Multicenter Phase II Study Incorporating DOXIL [doxorubicin liposomal] and Rituximab Into the Magrath [vincristine, cyclophosphamide, methotrexate, cytarabine, ifosfamide, etoposide] Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma.

Trial Profile

A Multicenter Phase II Study Incorporating DOXIL [doxorubicin liposomal] and Rituximab Into the Magrath [vincristine, cyclophosphamide, methotrexate, cytarabine, ifosfamide, etoposide] Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Ifosfamide; Methotrexate; Rituximab; Vincristine
  • Indications Burkitt's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2019.
    • 15 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
    • 24 Sep 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top